Treatability Study Sample Clauses

Treatability Study. If necessary, Respondents shall perform a Treatability Study (TS) to evaluate the effectiveness of a remedial technology (e.g., reactive cap). Preliminary (30%) RD. Respondents shall submit a Preliminary (30%) RD for the Project Area for EPA’s comment. All information and activities to be performed under the Preliminary (30%) RD shall be included and updated, as needed, in subsequent RD submittals (i.e., 60%, 95%, and 100%). The Preliminary RD must include: Intermediate (60%) RD. Respondents shall submit the Intermediate (60%) RD for EPA’s comment. The Intermediate RD must: (a) be a continuation and expansion of the Preliminary RD; (b) address EPA’s comments regarding the Preliminary RD; and (c) include the same elements as are required for the Preliminary (30%) RD. Pre-Final (95%) RD. Respondents shall submit the Pre-final (95%) RD for EPA’s comment. The Pre-final RD must be a continuation and expansion of the previous design submittal and must address EPA’s comments regarding the Intermediate RD. The Pre- final RD will serve as the approved Final (100%) RD if EPA approves the Pre-final RD without comments. The Pre-final RD must include: Final (100%) RD. Respondents shall submit the Final (100%) RD for EPA approval. The Final RD must address EPA’s comments on the Pre-final RD and must include final versions of all Pre-final deliverables.
View SourceView Similar (2)
Treatability Study. If determined necessary by EPA, Respondent shall perform a Treatability Study (TS) to evaluate the effectiveness of a remedial technology (e.g., reactive cap).
View Source
Treatability Study. If necessary, Respondents shall perform a Treatability Study (TS) to evaluate the effectiveness of a remedial technology (e.g., reactive cap). (a) Respondents shall submit a TS Work Plan (TSWP) for EPA comment and approval. Respondents shall prepare the TSWP in accordance with EPA’s Guide for Conducting Treatability Studies under CERCLA, Final (Oct. 1992), as supplemented for RD by the Remedial Design/Remedial Action Handbook, EPA 540/R-95/059 (June 1995). (b) Following completion of the TS, Respondents shall submit a TS Evaluation Report for EPA comment and approval. (c) EPA may require Respondents to supplement the TS Evaluation Report and/or to perform additional treatability studies.
View Source
Treatability Study. If potential remedial actions involving treatment have been identified by EPA or Respondent, Respondent shall conduct treatability studies, except where the Respondent can demonstrate to EPA’s satisfaction that they are not needed. Respondent shall provide EPA with the following deliverables for review:
View Source

Related to Treatability Study

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Feasibility Study Buyer is granted the right to conduct engineering and/or market and economic feasibility studies of the Property and a physical inspection of the Property, including studies or inspections to determine the existence of any environmental hazards or conditions (collectively, the “Feasibility Study”) during the period (the “Feasibility Period”) commencing on the Effective Date and ending at 5:00 p.m., Central Time, on the June 3, 2010. With Seller’s permission, after Seller has received advance notice sufficient to permit it to schedule in an orderly manner Buyer’s examination of the Property and to provide at least 24-hours’ advance written notice to any affected tenants, Buyer or its designated agents may enter upon the Property during normal business hours for purposes of analysis or other tests and inspections which may be deemed necessary by Buyer for the Feasibility Study. Buyer or its designated representative must be accompanied by a designated representative of Seller or have received Seller’s written permission prior to entering upon the Property in connection with Buyer’s Feasibility Study; provided, however, Buyer may not enter into any space leased by any tenant without being accompanied by a designated representative of Seller. Seller agrees to make its representative reasonably available during normal business hours. Buyer will not alter the physical condition of the Property or conduct invasive testing without notifying Seller of its requested tests, and obtaining the written consent of Seller to any physical alteration of the Property or invasive testing. Buyer will utilize commercially reasonable diligence to conduct or cause to be conducted all inspections and tests in a manner and at times which will not unreasonably interfere with any tenant’s use and occupancy of the Property. If Buyer determines, in its sole judgment, that the Property is not suitable for any reason for Buyer’s intended use or purpose, or is not in satisfactory condition, then Buyer may terminate this Contract by written notice to Seller prior to expiration of the Feasibility Period, in which case the ▇▇▇▇▇▇▇ Money (other than the Option Money) will be returned to Buyer, and neither party shall have any further right or obligation hereunder other than as set forth herein with respect to rights or obligations which survive termination. If this Contract is not terminated pursuant to this Section 5(a), then after expiration of the Feasibility Period, after Seller has received advance notice sufficient to permit it to schedule in an orderly manner Buyer’s examination of the Property and to provide at least 24-hours’ advance written notice to any affected tenants, Buyer or its designated agents may enter upon the Property during normal business hours. Buyer or its designated representative must be accompanied by a designated representative of Seller or have received Seller’s written permission prior to entering upon the Property; provided, however, Buyer may not enter into any space leased by any tenant without being accompanied by a designated representative of Seller. If this Contract is not timely terminated pursuant to this Section 5(a), Buyer’s right to terminate this Contract pursuant to this Section 5(a) and any and all objections with respect to the Feasibility Study will be deemed to have been waived by Buyer for all purposes.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.